Original Publications

Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A
Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
Rheumatol Int. 2017 Nov 16. doi: 10.1007/s00296-017-3870-7. [Epub ahead of print]

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.

Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A
Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort
Ann Rheum Dis. 2017 Sep;76(9):1583-1590. doi: 10.1136/annrheumdis-2017-211209.

Albrecht K, Richter A, Meissner Y, Huscher D, Baganz L, Thiele K, Schneider M, Strangfeld A, Zink A.
Wie häufig sind prognostisch ungünstige Faktoren bei Patienten mit rheumatoider Arthritis?
Z Rheumatol. 2017 Jun;76(5):434-442. doi: 10.1007/s00393-017-0306-4.

Richter A, Meißner Y, Strangfeld A, Zink A
Primary and secondary patient data in contrast: the use of observational studies like RABBIT
Clin Exp Rheumatol. 2016 Sept-Oct;34 Suppl 101(5):79-86. Review.

Pattloch D, Richter A, Manger B, Dockhorn R, Meier L, Tony H-P, Zink A, Strangfeld A
Das erste Biologikum bei rheumatoider Arthritis: Einflussfaktoren auf die Therapieentscheidung
Z Rheumatol. 2017 Apr;76(3):210-218. doi: 10.1007/s00393-016-0174-3.

Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A
Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
Arthritis Res Ther. 2016 Aug 5;18(1):183. doi: 10.1186/s13075-016-1077-z

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Ann Rheum Dis doi:10.1136/annrheumdis-2016-209773.

Albrecht K, Richter A, Callhoff J, Huscher D, Schett G, Strangfeld A, Zink A.
Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases.
Arthritis Res Ther. 2016 Jun 23;18:149. doi: 10.1186/s13075-016-1043-9.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J.
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.

Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A.
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.
Ann Rheum Dis. 2016 Sep;75(9):1667-73. doi: 10.1136/annrheumdis-2015-207838. Epub 2015 Nov 13.

Gerhold K, Richter A, Schneider M, Bergerhausen HJ, Demary W,
Liebhaber A, Listing J, Zink A, Strangfeld A.
Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Rheumatology (Oxford). 2015 Oct;54(10):1858-66. doi: 10.1093/rheumatology/kev194. Epub 2015 May 21.

Zink A, Sieper J.
Von der Ungewissheit zur Evidenz: Moderne Statistik in der Rheumatologie.
Z Rheumatol. 2015 Mar;74(2):104-5

Strangfeld A, Richter A.
Wie unterstützen Registerdaten die klinische Entscheidungsfindung?
Z Rheumatol. 2015 Mar;74(2):119-24

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.
Rheumatology (Oxford). 2015 Jun;54(6):1074-9. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.

Strangfeld A, Zink A.
Sicherheit unter Biologika – Ergebnisse aus dem deutschen Biologika-Register RABBIT.
Dtsch Med Wochenschr. 2014 Sep;139(37):1817-20

Krüger K, Strangfeld A, Kneitz C.
Sicherheit der Rheumatherapie im Alter.
Z Rheumatol. 2014;73(3):244-250

Kneitz C, Strangfeld A, Krüger K.
Prophylaxe und Behandlung von Infektionen beim älteren Rheumapatienten.
Z Rheumatol. 2014;73(3):225-232

Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, Zink A.
Sustainability of rituximab therapy in different treatment strategies – results of a 3-year follow-up of the German biologics register RABBIT.
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627-33.

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A.
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab.
Ann Rheum Dis. 2015 Feb;74(2):415-21.

Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A.
Evaluation of the RABBIT Risk Score for serious infections.
Ann Rheum Dis. 2014 Sep;73(9):1673-6.

Listing J, Gerhold K, Zink A.
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.
Rheumatology. 2013;52(1):53-61

Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J.
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
Ann Rheum Dis. 2011;70(11):1914-20

Gäwert L, Hierse F, Zink A, Strangfeld A.
How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register.
Rheumatology. 2011;50(1):152-160

Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, Zink A.
Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Rheumatology. 2011;50(1): 146-151

Gäwert L, Hierse F, Zink A, Strangfeld A.
Die Bedeutung der Patientensicht bei der Erfassung der Sicherheit neuer Medikamente.
Z Rheumatol. 2010;69(9):795–802

Zink A, Schneider M.
10 Jahre Behandlung mit TNF-Inhibitoren – Sind wir auf der sicheren Seite?
Z Rheumatol. 2010;69(9):772-773

Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A.
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
Seminars in Arthritis and Rheumatism. 2010;40(1):2-14

Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A.
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
Arthritis Res Ther. 2010;12(1):R5.

Strangfeld A, Gäwert L, Bussmann A, Gräßler A, Wilden E, Listing J, Zink A.
Therapie mit Biologika bei älteren Patienten mit rheumatoider Arthritis – Ergebnisse aus dem deutschen Biologika-Register RABBIT. Treatment with biologics in Older Patients with Rheumatoid Arthritis – Results from the German Biologics Register Rabbit.
Akt Rheumatol. 2009;34:291–298

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
Risk of Herpes Zoster in patients with rheumatoid arthritis treated with anti-TNFalpha agents.
JAMA. 2009;301(7):737-744

Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.
Comparative effectiveness of TNFalpha inhibitors in combination with either methotrexate or leflunomide.
Ann Rheum Dis. 2009;68:1856-1862

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.
Does Tumor Necrosis Factor alpha Inhibition Promote or Prevent Heart Failure in Patients With Rheumatoid Arthritis?
Arthritis Rheum. 2008;58(3):667-677

Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J.
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Arthritis Rheum. 2006;54(11):3399-407

Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A.
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register.
Arthritis Res Ther. 2006;8:R66

Zink A, Listing J, Strangfeld A, Gromnica-Ihle E, Demary W, Schneider M.
Dosisanpassung bei Patienten mit rheumatoider Arthritis unter Therapie mit Infliximab in der rheumatologischen Versorgung in Deutschland – Ergebnisse aus dem Biologika-Register RABBIT.
Z Rheumatol. 2006;65:441-446

Listing J, Strangfeld, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A.
Infections in patients with rheumatoid arthritis treated with biologic agents.
Arthritis Rheum. 2005;52(11):3403-12

Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R.
Treatment Continuation in Patients Receiving Biological Agents;or Conventional DMARD Therapy.
Ann Rheum Dis. 2005;64(9):1274-1279